Crucell Announces PER.C6® Commercial Licensing Agreement with ADImmune Corporation

Leiden, The Netherlands, October 11, 2006 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) announced today that it has signed a non-exclusive PER.C6® commercial license agreement with the Taiwan-based vaccine company ADImmune Corporation.

ADImmune intends to use the PER.C6® cell line technology to develop and commercialize a vaccine against Japanese encephalitis virus in Taiwan and China.

Under the terms of the agreement, ADImmune will pay a license issuance fee, annual maintenance fees and royalties on future product sales. Further financial details were not disclosed.

About Crucell
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. Its vaccines are sold in public and private markets worldwide. Crucell’s core portfolio includes a vaccine against hepatitis B and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, including both early-stage products and products almost ready to go to market. Several Crucell products are based on its unique PER.C6® production technology. The Company licenses this and other technologies to the biopharmaceutical industry. Important partners and licensees include DSM Biologics, sanofi aventis, GSK and Merck & Co. Crucell is headquartered in Leiden (the Netherlands), with subsidiaries in Switzerland, Spain, Italy and Korea. The Company employs about 900 people. For more information, please visit www.crucell.com.

About ADImmune
ADImmune Corporation is a biopharmaceutical company with demonstrated expertise in vaccine product development and manufacturing, and is the only privately owned human-use vaccine manufacturer in Taiwan. The company’s current vaccine products including tetanus toxoid products, Japanese encephalitis vaccine, and influenza vaccine are provided to the government, hospitals, and clinics of Taiwan’s domestic market with significant market share. The company is also conducting research and development in recombinant protein drugs and gene products to provide better medicines to patients. The recent success in the company’s self-developed serum-free and animal source-free media and cell culture technology platform provide the company with further strength in becoming a major biopharmaceutical player in the Asia-Pacific region. ADImmune is headquartered in Taichung, Taiwan, R.O.C. For more information, visit the company’s website at http://www.adimmune.com.tw.

Forward-looking statements
This press release contains forward-looking statements that involve inherent risks and uncertainties. We have identified certain important factors that may cause actual results to differ materially from those contained in such forward-looking statements. For information relating to these factors please refer to our Form 20-F, as filed with the U.S. Securities and Exchange Commission on July 6, 2006, and the section entitled “Risk Factors”. The Company prepares its financial statements under generally accepted accounting principles in the United States (US GAAP) and Europe (IFRS).

Contact Information

Paul Vermeij

Director Investor Relations and Corporate Communications

Crucell N.V.

Contact via E-mail